While these data explain the difference in SG sensitivity between cells with active DNA damage repair (DDR) pathways and those with impaired pathways in low Trop-2-expressing tumor cells, they do not separate these two potential biomarkers in terms of superiority. Here, TACSTD2 is linked to neoplasm.